Drug formularies: Myths-ln-formation

Medical Care

Volumn 28, Issue 10, 1990, Pages 928-942

  Donald Rucker, T ^a   Schiff, Gordon ^b  

^a UNIVERSITY OF MICHIGAN   (United States)

^b Jr Hospital of Cook County   (United States)

Author keywords

Drug formularies; Formularies; Pharmacy; Therapeutics committees

Indexed keywords

DRUG;

ARTICLE; ATTITUDE; HUMAN; PHARMACY AND THERAPEUTICS COMMITTEE; PHYSICIAN; PUBLICATION;

ATTITUDE OF HEALTH PERSONNEL; FORMULARIES, HOSPITAL; HUMAN; PHARMACEUTICAL PREPARATIONS; PHARMACY AND THERAPEUTICS COMMITTEE; PHYSICIANS;

EID: 0025500614     PISSN: 00257079     EISSN: 15371948     Source Type: Journal    
DOI: 10.1097/00005650-199010000-00007     Document Type: Article

References (70)

1. Health and Public Policy Committee, American College of Physicians. Improving medical education in therapeutics. Ann Intern Med 1988;108:145.
2. McCarron MM. Statement: hearings before the subcommittee on monopoly, select committee on small business, U.S. Senate, competitive problems in the drug industry. Washington, DC: GPO, 1967 (June 29):581.
3. Joint Commission on Accreditation of Hospitals. Accreditation manual for hospitals, 1965. Chicago: JCAH, 1965.
4. Rucker TD, Visconti JA. Relative drug safety and efficacy: any help for the practitioner? Am J Hosp Pharm 1979;36:1099.
5. Rucker TD. Formularies: conceptual and experiential factors related to drug product selection. Drug Information Journal 1982;16:118.
6. Rucker TD. Drug formularies: a basic bibliography. Hospital Pharmacy 1989;24:70.
7. Rucker TD. Effective formulary development: which direction? Top Hospital Pharmacy Management 1981;1:29.
8. Rucker TD. Pursuing rational drug therapy: a macro view a la the USA. Journal Social Administrative Pharmacy 1988;5:78.
9. Rucker TD. Quality control of hospital formularies. Pharmaceutisch Weekblad Scientific Edition 1988; 10:145.
10. Kanaraj S, Shatz SM, Kalies RF. Computer- based support system for formulary decisions. Am J Hosp Pharm 1987;44:1362.
11. Saskatchewan Health. Formulary. Regina: Saskatchewan Prescription Drug Services Branch, January, 1990:vi.
12. Abramowitz PW, Fletcher CV. Counterpoint: let’s expanded the formulary system and renew its vigor. Am J Hosp Pharm 1986;43:2836.
13. George CF, Hands DE. Drug and therapeutic committees and information pharmacy services: the United Kingdom. World Development 1983;11:229.
14. Plumridge RJ, Stoelwinder JU, Berbatis CG. Improving patient care and pharmacy management: the effect of hospital formularies. Drug Intell Clin Pharm 1984;18:652.
15. Fletcher RH, Fletcher SW, Wagner EH. Clinical epidemiology: the essentials. Baltimore, MD: Williams & Wilkins, 1988.
16. Sackett DL, Haynes RB, Tugwell P. Clinical epidemiology: a basic science for clinical medicine. Toronto: Little, Brown, 1985.
17. Larson EB. N-of-1 clinical trials: a technique for improving medical therapeutics. West J Med 1990;152:52.
18. Editorial. The FDA does not approve uses of drugs. JAMA 1984;252:1054.
19. Singh BN. Advances in the pharmacologic control of cardiac arrhythmias: focus on newer agents. Hospital Formulary 1987, 22:632.
20. Hine LK, Laird N, Hewitt P, et al. Meta-analysis of empirical long-term antiarrhytmic therapy after myocardial infarction. JAMA 1989;262:3037.
21. Sande MA. Need for controlled clinical studies in antimicrobial therapy. Ann Intern Med 1979;89:857.
22. Rucker TD. Quality control of hospital formularies. Pharmaceutisch Weekblad Scientific Edition 1988; 10:146.
23. Reinhardt UE. Resource allocation in health care: the allocation of lifestyles to providers. Milbank Mem Fund Q 1987;65:171.
24. Lee PR, Etheredge L. Clinical freedom: two lessons for the UK from US experience with privatisation of health care. Lancet 1989;(February 4):263.
25. Hampton JR. The end of clinical freedom. Br MedJ 1983;287:1237.
26. Vance MA, Millington WR. Principles of irrational drug therapy. Int J Health Serv 1986;16:355.
27. Kroenke K. Polypharmacy: causes, consequences, and cure. Am J Med 1985;79:149.
28. Davidson RA. Source of funding and outcome of clinical trials. J Gen Intern Med 1986;1:155.
29. Bukantz SC. Gold in the balance pan. Hosp Pract 1987;22:15.
30. May CD. Selling drugs by “educating” physicians. J Med Educ 1961;36:1.
31. Avom J, Chen M, Harley R. Scientific versus commercial sources of influence on the prescribing behavior of physicians. Am J Med 1982;73:4.
32. Modell W. Statement: Hearings before subcommittee on antitrust and monopoly, senate committee on the judiciary, 87th Congress (1st session), on senate resolution 52. 1961;320(Jul 20) S. 1552.
33. Fineberg HV, Pearlman LA. Surgical treatment of peptic ulcer in the united states. Lancet 1981;(June 13):1305.
34. Venning GR. Identification of adverse reactions to new drugs. Br Med J 1983;286:199.
35. McKinlay JB. From promising report to standard procedure: seven stages in the career of a medical innovation. Milbank Mem Fund Q 1981;59:374.
36. Rucker TD. The top-selling drug products: how good are they? Am J Hosp Pharm 1980;37:833.
37. Carson JL, Strom BL. Techniques of postmarketing surveillance: an overview. Medical Toxicology 1986;1:237.
38. Vestal RE. Methodological considerations for geriatric drug testing. Drug Information J 1985;19:435.
39. Carson JL, Strom BL. Techniques of postmarketing surveillance: an overview. Medical Toxicology 1986;1:237.
40. Steel K, Gertman PM, et al. Iatrogenic illness on a general medical service at a university hospital. N Engl J Med 1981;304:638.
41. Letters. Changing patterns of drug prescription. N Engl J Med 1983;309:1256.
42. Task Force on Prescription Drugs. The drug pre- scribers. Washington, DC: U.S. Department of Health, Education and Welfare, 1968;43.
43. Illinois Department of Public Health. Illinois formulary for the drug product selection program. Springfield: Illinois Department of Public Health, 1989 (February 28).
44. Medi-Span adds georgia to state formulary files. Indianapolis: Medi-Span, 1987 (October 4).
45. Jang R. Medicaid formularies: a critical review of the literature. Journal Pharmaceutical Marketing Management 1988;2:3 9.
46. Abramowitz PW, Fletcher CV. Counterpoint: let’s expand the formulary system and renew its vigor. Am J Hosp Pharm 1986;43:2835.
47. Pharmaceutical Manufacturers Association. Proceedings: restricted drug lists: bad medicine, bad economics? Washington: PMA, 1987 (April 23):1.
48. Johnson RC. Overview and objectives of drug program management. California Pharmacist 1978; 25:23.
49. Green JA. Point: the formulary system and the emperor’s new clothes. Am J Hosp Pharm 1986; 43:2830.
50. Dao TD. Marketing cost-effectiveness. Pharmaceutical Executive 1987;7(1):36.
51. Bakke OM. How many drugs do we need? World Health Forum 1986;7:252.
52. Rucker TD, Visconti JA. How effective are drug formularies? A description and normative study. Washington: ASHP Research & Education Foundation, 1978; 109.
53. Mossinghoff GJ. Quoted in: The Green Sheet 1987;36(48):3.
54. Rucker TD. Superior hospital formularies: a critical analysis. Hospital Pharmacy 1982;17:509.
55. Pharmaceutical Manufacturers Association. The health consequences of restricted drug lists. Washington, DC: PMA, 1985(November);17.
56. Soumerai SB, Ross-Degnan D, Gortmaker S, Avom J. Withdrawing payment for nonscientific therapy. JAMA 1990;263:831.
57. Rucker TD. The top-selling drug products: how good are they? Am J Hosp Pharm 1980;37:833.
58. Feldman A. HMOs try formularies in effort to curb prescription costs. Contract Health Care 1988;7:34.
59. Koberstein W. Mark knowles. Pharmaceutical Executive 1987;7(12):28.
60. Talley CR. Hospitals defend decisions against industry attacks. Am J Hosp Pharm 1978;35:1154.
61. Feather KR. Quoted in: Generic Line 1988;5:8.
62. Pfizer Pharmaceuticals. Drug formularies: an Rx for cost effectiveness? New York: Pfizer Pharmaceuticals, 1984.
63. Rucker TD. The top-selling drug products: how good are they? Am J Hosp Pharm 1980;37:836.
64. Rheinstein PH. Quoted in: PMA Newsletter 1988;30:4.
65. Pharmaceutical Manufacturers Association. Protecting medicaid patients from restrictive formularies. Washington, DC: PMA, 1990.
66. Pharmaceutical Manufacturers Association. The health care consequences of restricted drug lists. Washington, DC: PMA, 1985.
67. Koberstein W. Ernest mario. Pharmaceutical Executive 1988;8(1):32.
68. Grabowski HG. Medicaid patients’ access to new drugs. Health Affairs 1988;7:102-14.
69. Silverman M, Lee PR, Lydecker M. Pills & the public purse. Berkeley: University of California Press, 1981.
70. Task Force on Prescription Drugs. Final report. Washington, DC: U.S. Dept. Health, Education & Welfare, 1969:40.